Last reviewed · How we verify
SPH5030 tablets
At a glance
| Generic name | SPH5030 tablets |
|---|---|
| Sponsor | Shanghai Pharmaceuticals Holding Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors (EARLY_PHASE1)
- A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. (PHASE2)
- A Food Effect Study of SPH5030 Tablets. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPH5030 tablets CI brief — competitive landscape report
- SPH5030 tablets updates RSS · CI watch RSS
- Shanghai Pharmaceuticals Holding Co., Ltd portfolio CI